North China Pharmaceutical Group Corp
From Wikipedia, the free encyclopedia
North China Pharmaceutical Group Corp. (NCPC) is a leading pharmaceutical manufacturer in China. NCPC, in its early days, was one of the key construction projects during Chinese First Five-Year Plan. After fiver years of construction from the foundation date in June 1953, the successful operation started in June 1958. Being one of the world leading antibiotic producers both in technology and production scale at that time, NCPC created a history of commercial production of antibiotics in China. With 45 years development, NCPC has been continually growing and taking the lead in China pharmaceutical industry in key economic indexes, ranking one of the Top500 Enterprises and the best profit-makers in China. By the end of 2002, the total assets is USD2 billion, number of employees 18500. In 2002, NCPC achieved domestic sales revenue USD 700million and export sales USD100million. Sticking to the spirit of "Service for Life ", NCPC is willing to build bright future for all the people.[1]
Contents |
[edit] Organization
NCPC now has 29 subsidiaries. Among which North China Pharmaceutical Co., Ltd. is a listed company at Shanghai Stock Exchange with 59.87% of shaires held by NCPC. NCPC is one of the four groups of the candidate enterprises approved by China Securities Regulatory Commission for overseas listing. Keeping in close cooperation with foreign companies and institutions, NCPC has established 16 joint ventures and cooperative ventures.
[edit] Products
NCPC currently produces over 430 kinds of antibiotics, semi-synthetic antibiotics, pharmaceutical intermediates, vitamins, biotechnology products, veterinary and neutraceuticals both in bulk and in finished products. NCPC sells bulk antibiotics 7000 tons, vitamins 10000 tons, antibiotic intermediates 7500 tons, powder for injection 1.8 billion vials, capsules 1.03 billion grains annually. The capacity of penicillin, streptomycin, 6-APA, amoxycillin, cefaradine, vitamin B100 are in the lead worldwide. NCPC's next development focus is on biotechnology products, bio-pesticides and animal products. Since 1984, NCPC has initiated research on modern biotechnology and formed the system for developing generic drug involving new products R&D, pilot production and commercial production. In cooperation with the foreign companies, NCPC has completed the design and construction of GeneTech Biotechnology Co., Ltd. who is now a modern biotechnology production base in line with international practice and standards. There are rhGM-CSF, rhG-CSF, EPO and Hepatitis B Vaccine (CHO) on market at present.
[edit] QC & QA
NCPC established a rigorous and efficient quality control and quality assurance system. All of the processes in the production comply with the current GMP. The major production lines have passed the national GMP audit. The technology of NCPC's main products is in the leading position in China. Application of the latest technology and international advanced equipment ensures the stability of the production process and the product quality. NCPC was the first one in China who applied computer aided production management to fermentation process control. The CIMS Project of NCPC Beta Co., Ltd. has been awarded the National Model Project. NCPC has a Central QC Center of 7000 square meters with the advanced equipment and methods to control the quality in every production section. Through 20 years of TQM and unremitting efforts in quality improvement, an efficient quality assurance system has been established to guarantee the best quality of the products. In 2001, the trademark of NCPC was evaluated to be worth USD461million.
[edit] R&D
R&D As an enterprise with excellent abilities for independent research and development, NCPC was the first in China to succeed in developing dozen of new products: such as bacitracin, kasugamycin, bleomycin, amphotericin B, lindomycin, clindamycin, clindamycin phosphate and norvancomycin. NCPC New Drug R&D Co., Ltd. is responsible for the new drug and technology development of the whole NCPC Group. Nearly 300 experts and technicians, advanced instruments and integrated pilot unit make it possible to transform laboratory reactions into large-scale production. In recent 10 years, R&D investment of NCPC kept occupying over 30% of sales volume annually. Based on the long-term abundant input, NCPC has new products put into market every year. NCPC has been transferring from generic imitation into original research in new drug development and forming a development platform of its own. Its original research focuses on the natural and small molecular drugs screening, combinatorial chemical technology and modern biotechnology.
